Astanina E, Bussolino F, Doronzo G (2021) Multifaceted activities of transcription factor EB in cancer onset and progression. Mol Oncol 15(2):327–346. https://doi.org/10.1002/1878-0261.12867

Article  CAS  PubMed  Google Scholar 

Bounous G (2000) Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. Anticancer Res 20(6c):4785–4792

CAS  PubMed  Google Scholar 

Buzun K, Gornowicz A, Lesyk R, Bielawski K, Bielawska A (2021) Autophagy modulators in cancer therapy. Int J Mol Sci. https://doi.org/10.3390/ijms22115804

Article  PubMed  PubMed Central  Google Scholar 

Chai YC, Mieyal JJ (2023) Glutathione and glutaredoxin-key players in cellular redox homeostasis and signaling. Antioxidants. https://doi.org/10.3390/antiox12081553

Article  PubMed  PubMed Central  Google Scholar 

Chan Y-T, Zhang C, Wu J, Lu P, Xu L, Yuan H et al (2024) Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer 23(1):189. https://doi.org/10.1186/s12943-024-02101-z

Article  PubMed  PubMed Central  Google Scholar 

Che Z, Xue W, Zhao X, Hu C, Tian Y (2025) Regulatory role and biomarker potential of gut microbiota metabolites in the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) to hepatocellular carcinoma (HCC). Clin Transl Gastroenterol. https://doi.org/10.14309/ctg.0000000000000914

Article  PubMed  PubMed Central  Google Scholar 

Corà D, Bussolino F, Doronzo G (2021) TFEB signalling-related microRNAs and autophagy. Biomolecules. https://doi.org/10.3390/biom11070985

Article  PubMed  PubMed Central  Google Scholar 

Cucarull B, Tutusaus A, Hernáez-Alsina T, García de Frutos P, Reig M, Colell A et al (2021) Antioxidants threaten multikinase inhibitor efficacy against liver cancer by blocking mitochondrial reactive oxygen species. Antioxidants (Basel) 10:(9). https://doi.org/10.3390/antiox10091336

D’Arcy MS (2024) Mitophagy in health and disease. Molecular mechanisms, regulatory pathways, and therapeutic implications. Apoptosis 29(9–10):1415–1428. https://doi.org/10.1007/s10495-024-01977-y

Article  CAS  PubMed  Google Scholar 

Darmadi D, Rey I, Lubis M, Lindarto D, Muzasti RA (2025) CTLA-4 +6230G>A polymorphism and its impact on CTLA-4 level and risk of hepatocellular carcinoma: a case-control study in Batak patients with chronic hepatitis B. Narra J 5(2). https://doi.org/10.52225/narra.v5i2.1959

Article  PubMed  PubMed Central  Google Scholar 

El-Khoueiry AB, Hanna DL, Llovet J, Kelley RK (2021) Cabozantinib: an evolving therapy for hepatocellular carcinoma. Cancer Treat Rev 98. https://doi.org/10.1016/j.ctrv.2021.102221

Article  CAS  PubMed  Google Scholar 

Fu XY, Zhang X, Dong KS, Yu J (2023) Research progress on the mechanism of action of mitophagy in the occurrence and development of liver cancer. Zhonghua Gan Zang Bing Za Zhi 31(10):1113–1116. https://doi.org/10.3760/cma.j.cn501113-20220915-00470

Article  CAS  PubMed  PubMed Central  Google Scholar 

Groopman JD, Smith JW, Rivera-Andrade A, Alvarez CS, Kroker-Lobos MF, Egner PA et al (2021) Aflatoxin and the etiology of liver cancer and its implications for Guatemala. World Mycotoxin J 14(3):305–317. https://doi.org/10.3920/wmj2020.2641

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guerrero JJG, Encarnacion PC, Del Rosario MAS, Ora MAS, Zhou J, Notarte KI et al (2025) Genetic variants underlying precancerous conditions of hepatocellular carcinoma. Int J Cancer. https://doi.org/10.1002/ijc.70092

Article  PubMed  PubMed Central  Google Scholar 

Gumpper-Fedus K, Park KH, Ma H, Zhou X, Bian Z, Krishnamurthy K et al (2022) MG53 preserves mitochondrial integrity of cardiomyocytes during ischemia reperfusion-induced oxidative stress. Redox Biol. https://doi.org/10.1016/j.redox.2022.102357

Article  PubMed  PubMed Central  Google Scholar 

Kadenbach B (2021) Complex IV - the regulatory center of mitochondrial oxidative phosphorylation. Mitochondrion 58:296–302. https://doi.org/10.1016/j.mito.2020.10.004

Article  CAS  PubMed  Google Scholar 

Komza M, Chipuk JE (2025) Mitochondrial metabolism: a moving target in hepatocellular carcinoma therapy. J Cell Physiol 240(1). https://doi.org/10.1002/jcp.31441

Article  CAS  PubMed  Google Scholar 

Konyn P, Ahmed A, Kim D (2021) Current epidemiology in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 15(11):1295–1307. https://doi.org/10.1080/17474124.2021.1991792

Article  CAS  PubMed  Google Scholar 

Lee HY, Nga HT, Tian J, Yi HS (2021) Mitochondrial metabolic signatures in hepatocellular carcinoma. Cells. https://doi.org/10.3390/cells10081901

Article  PubMed  PubMed Central  Google Scholar 

Lu Y, Jiang Y, Liao X, Xiang J, Xu X, Han Y, et al (2025) ROS confer resistance to 3TC in p53 mutant colorectal cancer by promoting autophagy and ER stress. Eur J Pharmacol 1002177837. https://doi.org/10.1016/j.ejphar.2025.177837

Luque-Ceballos JC, Rodríguez-Zamora P, López-Olivos JC, Garzón IL (2023) Revisiting the scavenging activity of glutathione: free radicals diversity and reaction mechanisms. Comput Theor Chem 1227. https://doi.org/10.1016/j.comptc.2023.114227

Article  CAS  Google Scholar 

Ma Z, Chen W, Liu Y, Yu L, Mao X, Guo X et al (2024) Artesunate sensitizes human hepatocellular carcinoma to sorafenib via exacerbating AFAP1L2-SRC-FUNDC1 axis-dependent mitophagy. Autophagy 20(3):541–556. https://doi.org/10.1080/15548627.2023.2261758

Article  CAS  PubMed  Google Scholar 

Mino M, Kakazu E, Kanto T (2025) Precision strategy for hepatocellular carcinoma surveillance after hepatitis C cure: debates across guidelines. Gut Liver 19(5):651–664. https://doi.org/10.5009/gnl250187

Article  PubMed  PubMed Central  Google Scholar 

O’Sullivan Coyne G, Kummar S, Hu J, Ganjoo K, Chow WA, Do KT et al (2022) Clinical activity of single-agent cabozantinib (XL184), a multi-receptor tyrosine kinase inhibitor, in patients with refractory soft-tissue sarcomas. Clin Cancer Res 28(2):279–288. https://doi.org/10.1158/1078-0432.Ccr-21-2480

Article  PubMed  Google Scholar 

Rawat L, Balan M, Sasamoto Y, Sabarwal A, Pal S (2023) A novel combination therapy with cabozantinib and honokiol effectively inhibits c-Met-Nrf2-induced renal tumor growth through increased oxidative stress. Redox Biol. https://doi.org/10.1016/j.redox.2023.102945

Article  PubMed  PubMed Central  Google Scholar 

Scott AJ, Arcaroli JJ, Bagby SM, Yahn R, Huber KM, Serkova NJ et al (2018) Cabozantinib exhibits potent antitumor activity in colorectal cancer patient-derived tumor xenograft models via autophagy and signaling mechanisms. Mol Cancer Ther 17(10):2112–2122. https://doi.org/10.1158/1535-7163.Mct-17-0131

Article  CAS  PubMed  PubMed Central  Google Scholar 

Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S et al (2011) TFEB links autophagy to lysosomal biogenesis. Science 332(6036):1429–1433. https://doi.org/10.1126/science.1204592

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sharafi F, Rismani E, Rhmanian M, Khosravi A, Zarrabi A, Vosough M (2025) Mitochondrial dysfunction in hepatocellular carcinoma: from metabolism to targeted therapies. Mol Cell Biochem. https://doi.org/10.1007/s11010-025-05377-x

Article  PubMed  Google Scholar 

Shi Y, Zhang X, Wong T, Yan T, Henry L, Cheung R et al (2025) Sex differences in risk of adverse liver events in patients with cirrhosis. JAMA Netw Open 8(7):e2523674. https://doi.org/10.1001/jamanetworkopen.2025.23674

Article  PubMed  PubMed Central  Google Scholar 

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209–249. https://doi.org/10.3322/caac.21660